Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIM1803-1A
- Development stage
- Phase 1
- Lead developer
- Jiangsu Simsheng Pharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
SIM1803-1A is an orally available small molecule inhibitor targeting multiple receptor tyrosine kinases, specifically anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and tropomyosin receptor kinases (TRK; NTRK family). It is being developed for the treatment of solid tumors harboring wild-type or mutant NTRK, ROS1, or ALK gene fusions. The drug acts by blocking the activity of these kinases in cancer cells, thereby inhibiting tumor growth. Preclinical studies have shown high antitumor efficacy in models with relevant gene fusions. Clinical development has focused on patients with locally advanced or metastatic solid tumors that are positive for NTRK, ROS1, or ALK fusions[1][2][4][5][6].
- Other names
- SIM1803–1A
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)NTRK3 (Tropomyosin receptor kinase C)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)NTRK1 (Tropomyosin-related receptor kinase A)NTRK2 (Tropomyosin-related kinase receptor type B)
Beyond the preview
Go deeper on SIM1803-1A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM1803-1A.